Adding Bevacizumab Improves Overall Survival in NSCLC

TUESDAY, June 18, 2019 -- The addition of bevacizumab to carboplatin/pemetrexed is associated with improved overall survival among patients with advanced non-small cell lung cancer (NSCLC), according to a study published in the May issue of the...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news